Search

Your search keyword '"Maria Lucia Cascavilla"' showing total 2 results
Start Over Author "Maria Lucia Cascavilla" Journal annals of clinical and translational neurology
2 results on '"Maria Lucia Cascavilla"'

1. Idebenone increases chance of stabilization/recovery of visual acuity in OPA1‐dominant optic atrophy

Author

Martina Romagnoli, Chiara La Morgia, Michele Carbonelli, Lidia Di Vito, Giulia Amore, Corrado Zenesini, Maria Lucia Cascavilla, Piero Barboni, and Valerio Carelli

Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Abstract We previously documented that idebenone treatment in OPA1‐Dominant Optic Atrophy (OPA1‐DOA) led to some degrees of visual improvement in seven patients. We here present the results of a cohort study, which investigated the effect of off‐label idebenone administration in a larger OPA1‐DOA group compared with untreated patients. Inclusion criteria were: OPA1‐DOA clinical and molecular diagnosis, baseline visual acuity (VA) greater than/equal to counting fingers and treatment duration greater than 7 months. We found a significant difference between the last visit and baseline VA in favor of stabilization/recovery in idebenone‐treated as compared to untreated patients. This effect was retained after controlling for confounders.

Published
2020
Full Text
View/download PDF

2. Idebenone increases chance of stabilization/recovery of visual acuity in OPA1‐dominant optic atrophy

Author

Lidia Di Vito, Giulia Amore, Corrado Zenesini, Michele Carbonelli, Piero Barboni, Maria Lucia Cascavilla, Martina Romagnoli, Valerio Carelli, Chiara La Morgia, Romagnoli M., La Morgia C., Carbonelli M., Di Vito L., Amore G., Zenesini C., Cascavilla M.L., Barboni P., and Carelli V.

Subjects
Male, 0301 basic medicine, Visual acuity, Ubiquinone, Treatment duration, Visual Acuity, DOA, Outcome assessment, OPA1, Antioxidants, GTP Phosphohydrolases, Cohort Studies, 0302 clinical medicine, Outcome Assessment, Health Care, Idebenone, Young adult, General Neuroscience, Middle Aged, Female, medicine.symptom, Brief Communications, medicine.drug, Cohort study, RC321-571, Adult, medicine.medical_specialty, endocrine system, Adolescent, Neurosciences. Biological psychiatry. Neuropsychiatry, Brief Communication, Young Adult, 03 medical and health sciences, Atrophy, Ophthalmology, Optic Atrophy, Autosomal Dominant, medicine, Humans, RC346-429, business.industry, Significant difference, Off-Label Use, visual recovery, medicine.disease, eye diseases, idebenone, 030104 developmental biology, Neurology (clinical), Neurology. Diseases of the nervous system, business, 030217 neurology & neurosurgery
Abstract

We previously documented that idebenone treatment in OPA1‐Dominant Optic Atrophy (OPA1‐DOA) led to some degrees of visual improvement in seven patients. We here present the results of a cohort study, which investigated the effect of off‐label idebenone administration in a larger OPA1‐DOA group compared with untreated patients. Inclusion criteria were: OPA1‐DOA clinical and molecular diagnosis, baseline visual acuity (VA) greater than/equal to counting fingers and treatment duration greater than 7 months. We found a significant difference between the last visit and baseline VA in favor of stabilization/recovery in idebenone‐treated as compared to untreated patients. This effect was retained after controlling for confounders.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results